GNPX Stock Summary and Trading Ideas (Genprex | NASDAQ:GNPX)

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Genprex trades on the NASDAQ stock market under the symbol GNPX.

As of April 24, 2026, GNPX stock price was flat at $1.02 with 599,752 million shares trading.

GNPX has a beta of 0.27, meaning it tends to be less sensitive to market movements. GNPX has a correlation of 0.00 to the broad based SPY ETF.

GNPX has a market cap of $2.32 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, GNPX traded as high as $2,120.00 and as low as $.96.

The top ETF exchange traded funds that GNPX belongs to (by Net Assets): VXF.

GNPX has underperformed the market in the last year with a price return of -92.3% while the SPY ETF gained +31.9%. GNPX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -64.1% and -11.3%, respectively, while the SPY returned +3.8% and +5.1%, respectively.

GNPX support price is $.94 and resistance is $1.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNPX shares will trade within this expected range on the day.